Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)

References

• Walther A, Johnstone E, Swanton C, et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9:489–499.
   Google Scholar
• Boussios S, Ozturk MA, Moschetta M, et al. The developing story of predictive biomarkers in colorectal cancer. J Pers Med. 2019;9:12.
   Google Scholar
• Zarkavelis G, Boussios S, Papadaki A, et al. Current and future biomarkers in colorectal cancer. Ann Gastroenterol. 2017;30:613–621.
   Google Scholar
• Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–618.
   Google Scholar
• Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012;18:890–900.
   Google Scholar
• Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713–1729.
   Google Scholar
• Hartley A-V, Martin M, Lu T. Epigenetic biomarkers and their therapeutic applications in colorectal cancer, advances in the molecular understanding of colorectal cancer: intechOpen
   Google Scholar
• Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135:1079–1099.
   Google Scholar
• Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG Island methylator phenotype in colorectal cancer. Proc Nat Acad Sci. 1999;96:8681–8686.
   Google Scholar
• Hawkins N, Norrie M, Cheong K, et al. CpG Island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 2002;122:1376–1387.
   Google Scholar
• Weisenberger DJ, Siegmund KD, Campan M, et al. CpG Island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787–793.
   Google Scholar
• van Rijnsoever M, Grieu F, et al. Characterisation of colorectal cancers showing hypermethylation at multiple CpG Islands. Gut. 2002;51:797–802.
   Google Scholar
• Min B-H, Bae JM, Lee EJ, et al. The CpG Island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer. 2011;11:344.
   Google Scholar
• Cohen SA, Wu C, Yu M, et al. Evaluation of CpG Island methylator phenotype as a biomarker in colorectal cancer treated with adjuvant oxaliplatin. Clin Colorectal Cancer. 2016;15:164–169.
   Google Scholar
• TNF receptor superfamily member 10c: National Center for Biotechnology.
   Google Scholar
• Shivapurkar N, Toyooka S, Toyooka KO, et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer. 2004;109:786–792.
   Google Scholar
• Bosch LJW, Trooskens G, Snaebjornsson P, et al. Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. Oncotarget. 2017;8:63140–63154.
   Google Scholar
• André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–2351.
   Google Scholar
• Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25:3456–3461.
   Google Scholar
• Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and Leukemia Group B protocol 89803. J Clin Oncol. 2009;27:1814–1821.
   Google Scholar
• Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009;15:7322–7329.
   Google Scholar
• Warren RS, Atreya CE, Niedzwiecki D, et al. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res off J Am Assoc Cancer Res. 2013;19:5777–5787.
   Google Scholar
• Weisenberger DJ, Campan M, Long TI, et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 2005;33:6823–6836.
   Google Scholar
• Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat. 1947;18:50–60.
   Google Scholar
• Cochran WG. The chi-square test of goodness of fit. Ann Math Stat. 1952;23:315–345.
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
   Google Scholar
• Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol. 1972;34:187–220.
   Google Scholar
• Bertagnolli MM, Redston M, Compton CC, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer–a study of CALGB 9581 and 89803. J Clin Oncol. 2011;29:3153–3162.
   Google Scholar
• Criekinge WV, Bosch LJ, Trooskens G, et al. Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer. J Clin Oncol. 2013;31: 3552-3552.
   Google Scholar
• Bosch LJ, Trooskens G, Snaebjornsson P, et al. Abstract 1155: promoter CpG Island hypermethylation of Decoy Receptor 1 (DCR1) is associated with poor response to irinotecan in colorectal cancer. Cancer Res. 2013;73: 1155-1155.
   Google Scholar
• Wang H, Yang T, Wu X. 5-Fluorouracil preferentially sensitizes mutant KRAS non-small cell lung carcinoma cells to TRAIL-induced apoptosis. Mol Oncol. 2015;9:1815–1824.
   Google Scholar
• Zhao XD, Deng HB, Lu CL, et al. Association of EGFR and KRAS mutations with expression of p-AKT, DR5 and DcR1 in non-small cell lung cancer. Neoplasma. 2017;64:182–191.
   Google Scholar
• Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. Genome Res. 2002 Jun;12(6):996–1006.
   Google Scholar